logo
7-year-old in Hamilton has rare condition with $300K annual treatment her family can't afford

7-year-old in Hamilton has rare condition with $300K annual treatment her family can't afford

CBC13-03-2025
Social Sharing
Ibrahim Hermus arrived in Canada in 2023 with hopes his young daughter, Cena, would receive the medical care she desperately needed for a rare condition.
But Ibrahim soon discovered that would not be the case.
Cena, 7, was born in Turkey. At age 2, she was diagnosed with proopiomelanocortin (POMC) deficiency. The rare, life-threatening disorder causes severe obesity at an early age.
According to the U.S. National Library of Medicine, people with the disorder have low levels of the hormone adrenocorticotropic (ACTH), which can come with other health-threatening complications.
Cena and her family arrived in Canada on Sep. 12, 2023, as refugees from Turkey. Before that, they lived in Syria but had to flee the war-torn country.
Ibrahim said Cena weighed around 165 pounds when they came to Canada, after deadly earthquakes hit both countries, and she's now around 220.
During a recent visit to the family's Hamilton Mountain home, Ibrahim said he's "very scared" for his daughter.
The treatment Cena needs — a medication called setmelanotide — is at least $300,000 during the first year, according to both the family and McMaster Children's Hospital, which has been giving care to the seven-year-old.
CBC Hamilton has seen the hospital documents recommending the treatment for Cena.
But that's a cost the family can't afford.
Condition makes breathing, going to school hard
At home, Cena has a shy demeanour and timid smile. She likes to hold onto a doll, which she says is her favourite, and loves playing with her little sister, Fatima.
According to her father, Cena loves to spend time playing with her toys, as well as painting and drawing.
But doing her favourite things can get difficult for Cena. Her condition makes her feel tired and unable to walk most of the time, and she's unable to attend school most days.
Cena also suffers from sleep apnea, often waking up in the middle of the night, unable to breathe. Ibrahim said she's also dealing with diabetes, liver problems and constant pain.
Along with obesity, people with POMC deficiency tend to have adrenal insufficiency, which can lead to periods of low blood sugar, seizures and high levels of a bilirubin, a toxic substance. Adrenal insufficiency can lead to death if not treated early, according to the U.S. National Library of Medicine.
Health Canada says one in 12 people has a rare disease; many of them are children.
CBC Hamilton reached out to the Canadian Organization for Rare Disorders to understand more about POMC deficiency in Canada, but did not receive a response before publication. The government of Canada has called POMC "very rare," citing the GlobalData Healthcare database.
In the U.S., fewer than 1,000 people have the condition, according to Department of Health and Human Services.
In Cena's case, the medication she needs is not covered by the Ontario Drug Benefit program.
A spokesperson from the Ontario Ministry of Health told CBC Hamilton that for drugs like Imcivree (setmelanotide) to be covered under the program, the manufacturer must submit a request saying it is being used for a specific medical condition — and the ministry says the manufacturer has not done that.
CBC Hamilton reached out to the manufacturer of Imcivree (setmelanotide) for comment but did not hear back before publication. The drug was approved by Health Canada for use here in 2023.
'My heart is broken for this family'
Ibrahim said neither he nor his wife has been able to work in Canada due to a language barrier and the constant medical appointments and level of care their daughter needs.
They get Ontario child benefit payments and food bank support from Mishka Social Services, an organization that helps the local Muslim community. Along with Cena, there are five other children — four at home who are two through 14 years old, and two adult children living in Canada.
Over the past six months, Rania Mohammed, a social service worker with Mishka, has been working closely with the couple and their kids.
"My heart is broken for this family," she told CBC Hamilton.
She said this has been a difficult time for the family, especially Ibrahim, who feels "overwhelmed, scared, nervous" about what will happen to Cena.
"He told me, 'Can you imagine the feeling when you see your loved one, my daughter, in front of me, and I cannot afford her medication? And I know if this won't be covered, I'm going to lose her,'" Mohammed said.
Ibrahim said the anxiety has taken a big toll on him and his health, and he often finds it hard to sleep.
Ozempic another option for Cena
But Ibrahim won't stop trying to help his daughter, Mohammed said.
Mishka Social Services has also been advocating for Cena. Since last year, the organization has set up a GoFundMe to raise money for her medication and is organizing a fundraising Iftar dinner during the holy month of Ramadan, with part of the proceeds going to help Cena, according to Mohammed. The dinner is Friday at Carmen's event centre.
While setmelanotide remains out of reach right now, Cena is taking some medication to ease symptoms.
Ozempic, a drug approved to treat diabetes, is also a temporary option to manage Cena's weight, Mohammed said. But even though it's less expensive — around $400 a month — the family says it does not fit in their budget.
With help from Mishka and other services, Cena's family has reached out to multiple organizations and local officials such as members of Parliament to raise awareness of their situation and ask for "any support available." They have yet to receive any as a result, Mohammed said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Canada is facing a nationwide shortage of these prescription painkillers
Canada is facing a nationwide shortage of these prescription painkillers

Global News

time2 hours ago

  • Global News

Canada is facing a nationwide shortage of these prescription painkillers

A national shortage of common prescription pain medications in Canada could last into early August. Health Canada issued a notice last week that drugs containing acetaminophen with codeine or oxycodone that are used to relieve pain are experiencing shortages. Acetaminophen with oxycodone is often under the brand Percocet, while acetaminophen combined with codeine is sometimes known as Tylenol No. 3. Other formulations include Teva-Oxycocet, Teva-Lenoltic No. 1, 2, 3 and 4, and Rivacocet. Some of the companies that manufacture both medication combinations, including Teva Canada Ltd., Laboratoire Riva Inc. and Pharmascience Inc., have reported issues around manufacturing disruptions and increased demands as causes of the shortages. The Canadian Pharmacists Association told Global News it's been working with Health Canada and is in communication with manufacturers and suppliers to assess the potential impact. Story continues below advertisement 2:21 Another health care hurdle Prescription medication shortages In response to the shortages, the CPA said pharmacists have been limiting amounts given to patients. Get weekly health news Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy 'Usually pharmacists have to dispense the amount that is being written on the prescription unless it is being limited by the drug plan,' said Sadaf Faisal, senior director of professional affairs at the CPA. 'In a situation like these, pharmacists are documenting on their prescriptions that we are only supplying 30 days right now because we don't have enough supply.' She said some pharmacists are also seeking out supplies from other pharmacies. According to the association, the shortages are expected to last until early August, when a 'significant resupply' is anticipated. What Canadians can do if impacted In its notice, Health Canada said that as the shortage continues, Canadians should speak with their doctor or pharmacist if they have concerns about the availability of either medication. Story continues below advertisement It says they may be able to offer other options if their specific medication is not available. 'Pharmacists and other health-care providers can help them (patients) navigate this shortage,' Faisal said. 'We can identify alternatives, we can provide guidance on safe and effective pain management, which is really important because it can impact quality of life for a lot of patients.' Faisal does caution, however, that due to the Controlled Drugs and Substances Act, pharmacists cannot change the prescription or offer an alternative without consulting the physician to approve the suggestion. While the shortage may end within a few weeks, Health Canada is also urging Canadians to only use a licensed pharmacy to get medication and only buy products authorized for sale in Canada. It also advises people to avoid buying from unlicensed and unverified online sellers, as the products may not contain the active ingredient or contain undeclared and hazardous ingredients.

Pura Scents recalling diffusers in U.S. and Canada as magnet issue may cause ingestion hazard
Pura Scents recalling diffusers in U.S. and Canada as magnet issue may cause ingestion hazard

Toronto Sun

time4 hours ago

  • Toronto Sun

Pura Scents recalling diffusers in U.S. and Canada as magnet issue may cause ingestion hazard

Published Jul 24, 2025 • 1 minute read Pura 4 Smart Home Fragrance Diffuser is pictured in this photo provided by Health Canada. Photo by Health Canada. Pura Scents is recalling more than 850,000 diffusers because some magnets may detach and cause a possible ingestion hazard to children. This advertisement has not loaded yet, but your article continues below. THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. SUBSCRIBE TO UNLOCK MORE ARTICLES Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors Don't have an account? Create Account The company is recalling about 851,400 Pura 4 Smart Home Fragrance Diffusers with detachable covers. It said an additional 1,100 were sold in Canada. Pura Scents said that the magnets on the inside cover of the product can detach, posing an ingestion hazard to children. When high-powered magnets are swallowed, the ingested magnets can attract each other, or other metal objects, and become lodged in the digestive system. This can result in perforations, twisting or blockage of the intestines, infection, blood poisoning and death. The company has received three reports of magnets detaching from the cover. No injuries have been reported. The diffusers were sold at Target, Scheels and other stores nationwide from August 2023 through May 2025 for about $50. They were also sold online through Pura's website, as well as online at Amazon, Target and Scheels. Pura Scents is offering a free replacement cover. Consumers are advised to immediately dispose of the existing detachable cover and to keep the diffusers out of the reach of children and pets. To receive the free replacement cover, individuals may contact Pura Scents at 855-394-5292 from 9 a.m. to 5 p.m. MT Monday through Friday. The company can also be emailed at replacement↕ Consumers may also visit the company's website and click on 'Recall' at the bottom of the page for more information. Sports Ontario Golf Canada Canada

Pramana Receives Health Canada Authorization for Digital Pathology Scanners
Pramana Receives Health Canada Authorization for Digital Pathology Scanners

National Post

time7 hours ago

  • National Post

Pramana Receives Health Canada Authorization for Digital Pathology Scanners

Article content CAMBRIDGE, Mass. — Pramana, an AI-enabled health tech company modernizing the pathology sector, today announced it has received Health Canada Medical Device Licenses for its flagship digital pathology scanners, the SpectralM and SpectralHT Cubiq systems. The approval authorizes Pramana to import, market, and sell its devices in Canada, expanding access to its advanced imaging and workflow solutions. Article content Health Canada authorization is required to commercialize Class II medical devices and affirms the product's safety, effectiveness, and quality. The approval opens the door for Pramana to support Canadian hospitals, pathology labs, and research institutions, helping modernize diagnostic workflows with scalable, AI-powered digital pathology tools. This recognition marks a critical step in Pramana's international expansion, building on its growing regulatory footprint. Article content 'Receiving Health Canada authorization is a major milestone in our commercialization strategy,' said Prasanth Perugupalli, Chief Product Officer at Pramana. 'It reflects the strength of our product development, quality, and regulatory readiness, and it opens the door to expanding access to our technology in a market known for strong clinical and academic institutions.' Article content Pramana's scanners are designed to digitize a wide range of pathology slides, producing high-resolution whole-slide images with automated quality control and AI-powered decision support. The platform supports both FFPE tissue and Liquid Based Cytology (LBC) samples prepared using methods such as the ThinPrep® Pap test (Hologic) and BD SurePath™ (Becton Dickinson). Unlike most digital pathology systems focused solely on anatomic pathology, Pramana expands digital workflows to include hematopathology, microbiology, and cytology, delivering flexibility across all major slide types. Article content 'Our research at the University of Toronto highlights the need for adaptable platforms that can manage these technical demands while still supporting routine histology and cytology workflows,' said Dr. Carlo Hojilla, Consultant Pathologist at the University of Toronto. 'Pramana's technology meets that standard, and its Health Canada authorization reflects both its clinical utility and the rigorous quality required for widespread adoption.' Article content Prior to receiving Health Canada authorization, Pramana secured Medical Device Single Audit Program (MDSAP) certification, a requirement that validated its quality management system and streamlined regulatory access in Canada, the United States, Brazil, Australia, and Japan, highlighting Pramana's commitment to modernizing digital pathology worldwide. Article content To discover how Pramana's whole-slide imaging solution can help healthcare organizations across Canada, visit Article content About Pramana, Inc. Article content Pramana is a health tech company transforming digital pathology with AI-powered imaging solutions that support seamless adoption across labs, health systems, and medical centers. Pramana's Spectral scanners deliver industry-leading image quality and unprecedented accuracy. Built-in AI algorithms and automated quality control streamline workflows, increase efficiency, and capture previously undetectable tissue features, empowering pathologists with the tools needed to improve clinical diagnostics and research. The company is headquartered in Cambridge, Mass. For more information, visit Article content Article content Article content Article content Article content Article content

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store